Danaher is building an AI lab that designs, makes and tests antibodies with robots in the loop

Danaher, the big maker of lab instruments and research tools, said on Wednesday, Oct. 7, 2026, that it plans to launch its first AI-powered autonomous lab. Based at its Abcam unit, the lab uses AI to design antibodies and other affinity reagents, then robots build and test each one and feed the results back into the model. Danaher says it should run at scale in early 2027.

Antibodies aren't just drugs; they're the basic test kit of biology, the tiny hooks researchers use to find and measure proteins in almost every experiment. Making a good one has traditionally meant months of work and, often, animals. Danaher is betting a robot loop can do that grind faster and at higher volume, and that matters because Danaher sells the tools a huge share of the world's labs already use, so if this works it won't stay a showroom demo. Two honest caveats: "up to 8x faster" is a company target for a lab that won't run at scale until 2027, and the product here is research reagents, not new medicines, so any payoff for patients comes further down the line. Still, this is the self-driving lab idea moving from university papers into a company that can actually ship it. The scientists stay in charge; the pipettes get a promotion.

On Wednesday, 7 October 2026, Danaher Corporation announced plans to launch its first AI-powered autonomous lab. The investor page is titled “Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab.” The dateline is Washington. The company’s shares trade on the New York Stock Exchange under the ticker DHR. The lab is designed to help researchers develop custom antibodies and other molecular tools faster. Danaher also calls those tools affinity reagents. An antibody is a protein the immune system uses to grab a target. Here the antibodies are research tools — the hooks scientists use to find and measure proteins — not medicines. An affinity reagent is any molecule made to stick to a chosen target. Danaher says the lab is expected to operate at scale in early 2027. Those lines are Danaher’s. PR Newswire carried the same text and stamped 7 October 2026, 7:00 a.m. Eastern, which is 11:00 UTC.

The lab is based at Abcam, a Danaher company. AI proposes new reagent designs. The lab then builds and tests each one and feeds every result back into the model, so the next design can be better. Danaher calls that a continuous design-make-test-learn loop. Design is proposing the molecule. Make is building it. Test is checking whether it works. Learn is sending the result back to the model. Those lines are Danaher’s.

The workflow pulls in technology from several Danaher companies: Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices. Device orchestration and robotic automation were built with Automata, a lab-automation company. Device orchestration means software that tells the instruments and robots what to do, in order. Those names are Danaher’s.

Danaher’s stated targets are up to 8 times faster discovery of affinity reagents, and up to a tenfold increase in annual reagent generation, from tens to hundreds of reagents a year as the lab scales. Eight times faster means a job that took eight weeks would take one, if the target holds. Tenfold means ten times as many reagents in a year. Each design is verified and tested. Over time, Danaher says, the approach is expected to complement traditional immunization-based methods for discovering antibodies. Immunization-based means making antibodies by exposing an animal to the target, the usual way. Complement means sit beside those methods, not replace them on day one. Those figures are Danaher’s targets. They are not a result the lab has already posted.

Julie Sawyer Montgomery, president and chief executive of Danaher, said: “It is an important step toward a future where AI, automation and intelligent systems dramatically accelerate the journey from discovery to impact.” That sentence is hers, on the announcement.

JC Gutierrez-Ramos, senior vice president and chief science officer, said: “Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds.” He said scientists continue to make the key decisions, so they can spend more time on the hard scientific questions. Those sentences are his, on the announcement.

Danaher calls the lab the first step in a broader push to build smart instruments that are easier to control with software, produce AI-ready data, and include expert-level agentic systems. Agentic, here, means software that can take a sequence of steps on its own. Those instruments can then be linked into autonomous labs that run the same design-make-test-learn cycle. Those lines are Danaher’s. The announcement does not name a second lab, a city for this one beyond Abcam, or a price.

Cris Tolomia at Quartz covered the same announcement the same day, under the headline “Danaher is launching an AI-powered autonomous lab for drug discovery.” Quartz’s frame is drug discovery. Danaher’s page is research reagents: custom antibodies and other molecular tools. The two are related — a better research antibody can help a drug project — but they are not the same product. Quartz reprints the 8-times and tenfold targets, the Abcam base, the operating-company list, and the two executive quotations. Those lines are Quartz’s account of the release.

In plain terms, Danaher said on Wednesday that it will open an AI-powered autonomous lab at Abcam, expected to run at scale in early 2027. The model designs antibodies and other affinity reagents; robots build and test them; every result goes back into the model. The company target is up to 8 times faster discovery and up to 10 times more reagents a year, from tens to hundreds, as the lab scales. Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, Molecular Devices, and Automata sit in the workflow. The chief executive called it a step toward faster discovery. The chief science officer said scientists stay in charge of the key decisions. The 8-times and tenfold figures are company targets for a lab that is not at scale yet. The product is research reagents, not a new medicine.